FDA Accepts Cogent Biosciences' New Drug Application For Bezuclastinib In Patients With NonAdvanced Systemic Mastocytosis - Cogent Biosciences (NASDAQ:COGT)
Published on March 16, 2026.
The FDA has accepted the New Drug Application for Bezuclastinib, a form of treatment for patients with non-advanced systemic Mastocytosis. The application is part of a larger effort to combat this issue. The company is also working with the University of California, where it operates under the influence of the pharmaceutical industry.
Related Articles
Coleman’s new folding cooler stays cold for up to 64 hours.
Coleman's new folding cooler, featuring folding walls and a flexible liner, is available for sale online for $1.
Glencore turns to China exchange stocks to meet cobalt commitments, sources say
Glencore uses Wuxi exchange stocks to meet cobalt commitments due to limited supplies in Congo, which have led to significant price increases.
Apple’s $549 AirPods Max 2 add better ANC and live translation
Apple's AirPods Max 2 offers enhanced noise cancellation, advanced audio, and a real-time translation, all for $549.